Table 1.
Presurgical clinical and biochemical features of patients with adrenal incidentalomas and without (PSH–) or with postsurgical hypocortisolism (PSH+)
| Group PSH+n = 39 | Group PSH-n = 21 | P value | |
|---|---|---|---|
| Females | 31 | 15 | .532 |
| Age (years) | 55.3 ± 12.0 (24-74) | 57.2 ± 8.3 (33-75) | .505 |
| BMI (kg/m2) | 27.4 ± 5.6 (17.4-41) | 29.6 ± 5.4 (21.5-41) | .163 |
| Reason for surgery (size of the mass/SH) | 18/21 | 13/8 | .287 |
| HC doses (mg/day) | 20.9 ± 2.6 [20, 30] | 20.9 ± 2.3 [20, 30] | .932 |
| ACTH (pg/mL) | 9.6 ± 5.7 (1.9-26.9) | 9.0 ± 4.4 (5.0-23.8) | .665 |
| ACTH >26.9 pg/mL (%) | 0 (0.0) | 1 (1.7) | .650 |
| F-1mg-DST (µg/dL) | 4.6 ± 3.5 (1.2-13.7) | 3.2 ± 2.1 (0.9-9.0) | .098 |
| F-1mg-DST <1.2 µg/dL (%) | 0 (0.0) | 9 (42.9) | <.0001 |
| UFC (µg/24 hours) | 68.2 ± 45.2 (10.4-189.6) | 51.3 ± 32.4 (10.0-120.0) | .136 |
| UFC <10.4 µg/24 hours | 0 (0.0) | 2 (9.5) | .119 |
| MSC (µg/dL) | 6.0 ± 3.1 (1.2-12.5) | 3.4 ± 2.0 (1.0-8.0) | .001 |
| MSC <1.2 µg/dL | 0 (0.0) | 1 (4.8) | .350 |
| Diameter of adenoma (cm) | 3.5 ± 1.3 (1.2-9.0) | 3.2 ± 1.0 (1.5-5.7) | .340 |
| Pts with type 2 diabetes mellitus (%) | 9 (23.1) | 5 (23.8) | 1.000 |
| Pts with arterial hypertension (%) | 18 (46.2) | 15 (71.4) | .102 |
| Pts with obesity (%) | 15 (38.5) | 10 (47.6) | .587 |
| Pts with dyslipidemia (%) | 12 (30.8) | 10 (47.6) | .263 |
| Pts with metabolic syndrome (%) | 5 (12.8) | 6 (28.6) | .169 |
For plasma cortisol multiply × 27.56 to convert from µg/dL to nmol/L. For 24 hour urinary cortisol multiply × 2.756 to convert from µg/24 hours to nmol/24 hours. For ACTH multiply × 0.22 to convert from pg/mL to pmol/L.
Abbreviations: ACTH, adrenocorticotropin; Pts, patients; PSH, postsurgical hypercortisolism; PSH–, absence of PSH; PSH+, presence of PSH; MSC, midnight serum cortisol; UFC, urinary free cortisol; F-1mgDST, cortisol after 1 mg overnight dexamethasone suppression test; HC, hydrocortisone dose during substitutive therapy period.